Psychedelics and schizophrenia

Research on psychedelics such as lysergic acid diethylamide (LSD) and dissociative drugs such as phencyclidine (PCP) and the symptoms, neurochemical abnormalities and treatment of schizophrenia have converged. The effects of hallucinogenic drugs resemble some of the core symptoms of schizophrenia. Some atypical antipsychotic drugs were identified by their high affinity for serotonin 5-HT(2A) receptors, which is also the target of LSD-like drugs. Several effects of PCP-like drugs are strongly affected by both 5-HT(2A) and metabotropic glutamate 2/3 receptor modulation. A serotonin-glutamate receptor complex in cortical pyramidal neurons has been identified that might be the target both of psychedelics and the atypical and glutamate classes of antipsychotic drugs. Recent results on the receptor, signalling and circuit mechanisms underlying the response to psychedelic and antipsychotic drugs might lead to unification of the serotonin and glutamate neurochemical hypotheses of schizophrenia.

[1]  D. Lorrain,et al.  Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 , 2003, Neuroscience.

[2]  B. Moghaddam,et al.  Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex , 2001, Biological Psychiatry.

[3]  B. Morris,et al.  PCP: from pharmacology to modelling schizophrenia. , 2005, Current opinion in pharmacology.

[4]  A. Carlsson,et al.  The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice , 1999, Journal of Neural Transmission.

[5]  H. Schoemaker,et al.  Habituation Deficits Induced by Metabotropic Glutamate Receptors 2/3 Receptor Blockade in Mice: Reversal by Antipsychotic Drugs , 2007, Journal of Pharmacology and Experimental Therapeutics.

[6]  B. Dean,et al.  Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia , 2008, Schizophrenia Research.

[7]  B. Dean.  The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice , 2003, Journal of neurochemistry.

[8]  J. Gewirtz,et al.  Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors , 2002, Pharmacology Biochemistry and Behavior.

[9]  J. Lieberman,et al.  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs , 2005, Molecular Psychiatry.

[10]  K. Murnane,et al.  The behavioral pharmacology of hallucinogens. , 2008, Biochemical pharmacology.

[11]  E. Jodo,et al.  Acute administration of phencyclidine induces tonic activation of medial prefrontal cortex neurons in freely moving rats , 2002, Neuroscience.

[12]  C. Corti,et al.  The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity , 2008, Psychopharmacology.

[13]  C. Swanson,et al.  The Group II Metabotropic Glutamate Receptor Agonist (−)-2-Oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and Clozapine Reverse Phencyclidine-Induced Behaviors in Monoamine-Depleted Rats , 2002, Journal of Pharmacology and Experimental Therapeutics.

[14]  J. Gewirtz,et al.  Behavioral Evidence for Interactions between a Hallucinogenic Drug and Group II Metabotropic Glutamate Receptors , 2000, Neuropsychopharmacology.

[15]  P S Goldman-Rakic,et al.  5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Deutch,et al.  DOI-Induced Activation of the Cortex: Dependence on 5-HT2A Heteroceptors on Thalamocortical Glutamatergic Neurons , 2000, The Journal of Neuroscience.

[17]  P. Celada,et al.  Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine , 2007, Proceedings of the National Academy of Sciences.

[18]  L. Bohn,et al.  Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo , 2008, Proceedings of the National Academy of Sciences.

[19]  A. Deutch,et al.  Serotonin 5‐HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex , 1997, Synapse.

[20]  W. Spooren,et al.  Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. , 2000, European journal of pharmacology.

[21]  Stuart C. Sealfon,et al.  Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior , 2007, Neuron.

[22]  Marta Filizola,et al.  Dopamine D2 receptors form higher order oligomers at physiological expression levels , 2008, The EMBO journal.

[23]  R. Lefkowitz,et al.  Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. , 1993, Trends in pharmacological sciences.

[24]  S Marenco,et al.  Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk , 2008, Molecular Psychiatry.

[25]  G. Marek.  Metabotropic glutamate 2/3 receptors as drug targets. , 2004, Current opinion in pharmacology.

[26]  Graeme Milligan,et al.  G protein-coupled receptor dimerisation: molecular basis and relevance to function. , 2007, Biochimica et biophysica acta.

[27]  Thomas W. Mühleisen,et al.  Large recurrent microdeletions associated with schizophrenia , 2008, Nature.

[28]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[29]  G. Aghajanian,et al.  Serotonin model of schizophrenia: emerging role of glutamate mechanisms , 2000, Brain Research Reviews.

[30]  S. Rees,et al.  Reporter-gene systems for the study of G-protein-coupled receptors. , 2001, Current opinion in pharmacology.

[31]  D. Schoepp,et al.  Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (–)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039) , 2008, Journal of Pharmacology and Experimental Therapeutics.

[32]  T. Kameyama,et al.  Phencyclidine-induced head-twitch responses as 5-HT2 receptor-mediated behavior in rats , 1987, Neuroscience Letters.

[33]  P. Celada,et al.  The Hallucinogen DOI Reduces Low-Frequency Oscillations in Rat Prefrontal Cortex: Reversal by Antipsychotic Drugs , 2008, Biological Psychiatry.

[34]  K. Heekeren,et al.  Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers , 2005, Pharmacopsychiatry.

[35]  F. Colpaert.  Discovering risperidone: the LSD model of psychopathology , 2003, Nature Reviews Drug Discovery.

[36]  P. Celada,et al.  In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. , 2003, Cerebral cortex.

[37]  Graeme Milligan,et al.  The α1b-Adrenoceptor Exists as a Higher-Order Oligomer: Effective Oligomerization Is Required for Receptor Maturation, Surface Delivery, and Function , 2007, Molecular Pharmacology.

[38]  Graeme Milligan,et al.  Identification of a serotonin/glutamate receptor complex implicated in psychosis , 2008, Nature.

[39]  Henry A. Nasrallah,et al.  Schizophrenia, “Just the Facts”: What we know in 2008 Part 1: Overview , 2008, Schizophrenia Research.

[40]  E. Jodo,et al.  Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway. , 2005, Cerebral cortex.

[41]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[42]  J. John Mann,et al.  Higher Postmortem Prefrontal 5-HT2A Receptor Binding Correlates with Lifetime Aggression in Suicide , 2006, Biological Psychiatry.

[43]  Henry A. Nasrallah,et al.  Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology , 2008, Schizophrenia Research.

[44]  Franz X Vollenweider,et al.  Serotonin research: contributions to understanding psychoses. , 2008, Trends in pharmacological sciences.

[45]  M. O'Neill,et al.  Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine. , 1998, The Journal of pharmacology and experimental therapeutics.

[46]  E. sanders-Bush,et al.  Chronic Phenethylamine Hallucinogen Treatment Alters Behavioral Sensitivity to a Metabotropic Glutamate 2/3 Receptor Agonist , 2008, Neuropsychopharmacology.

[47]  Brian Dean,et al.  5-HT2A and muscarinic receptors in schizophrenia: a postmortem study , 2005, Neuroscience Letters.

[48]  Paul J. Harrison,et al.  5-HT1A and 5-HT2A Receptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia , 1996, Neuropsychopharmacology.

[49]  T. Kaneko,et al.  Pre- and postsynaptic localization of a metabotropic glutamate receptor, mGluR2, in the rat brain: an immunohistochemical study with a monoclonal antibody , 1996, Neuroscience Letters.

[50]  F. Artigas,et al.  Clozapine and Haloperidol Differently Suppress the MK-801-Increased Glutamatergic and Serotonergic Transmission in the Medial Prefrontal Cortex of the Rat , 2007, Neuropsychopharmacology.

[51]  A. Singleton,et al.  Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia , 2008, Science.

[52]  T. Si,et al.  Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors. , 2007, European journal of pharmacology.

[53]  E. Nisenbaum,et al.  Group II Metabotropic Glutamate Receptor Modulation of DOI-induced c-fos mRNA and Excitatory Responses in the Cerebral Cortex , 2003, Neuropsychopharmacology.

[54]  J. Joyce,et al.  Alterations in the cortical serotonergic system in schizophrenia: A postmortem study , 1997, Biological Psychiatry.

[55]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[56]  P. Visscher,et al.  Rare chromosomal deletions and duplications increase risk of schizophrenia , 2008, Nature.

[57]  J. Gewirtz,et al.  A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex , 2001, Neuroscience.

[58]  H. Meltzer.  Treatment of Suicidality in Schizophrenia , 2001, Annals of the New York Academy of Sciences.

[59]  J. C. Winter,et al.  Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli , 2004, Psychopharmacology.

[60]  N. Mizuno,et al.  Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody , 1998, Neuroscience Research.

[61]  R. Poulton,et al.  Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. , 2008, Schizophrenia bulletin.

[62]  W. Park,et al.  NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in mice. , 1998, Life sciences.

[63]  Z. Xiang,et al.  A Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 2 Blocks a Hallucinogenic Drug Model of Psychosis , 2007, Molecular Pharmacology.

[64]  Terry Kenakin,et al.  Ligand-selective receptor conformations revisited: the promise and the problem. , 2003, Trends in pharmacological sciences.

[65]  T. dePaulis.  M-100907 (Aventis). , 2001 .

[66]  G. Aghajanian,et al.  Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release , 1999, Brain Research.

[67]  Akira Sawa,et al.  Schizophrenia: Diverse Approaches to a Complex Disease , 2002, Science.

[68]  E. Bullmore,et al.  Psychological effects of ketamine in healthy volunteers , 2006, British Journal of Psychiatry.

[69]  J. Guimón,et al.  Effects of Age, Postmortem Delay and Storage Time on Receptor-mediated Activation of G-proteins in Human Brain , 2002, Neuropsychopharmacology.

[70]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[71]  J. Gogos,et al.  Modeling Madness in Mice: One Piece at a Time , 2006, Neuron.

[72]  R. Shigemoto,et al.  Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites , 2001, Neuroscience.

[73]  K. Perry,et al.  Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade , 2001, Neuropharmacology.

[74]  Sarah A. J. Reading,et al.  Neurobiology of Schizophrenia , 2006, Neuron.

[75]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[76]  A. Bortolozzi,et al.  Stimulation of α1‐adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5‐hydroxytryptamine release: reversal by antipsychotic drugs , 2003, Journal of neurochemistry.

[77]  Yogesh K. Dwivedi,et al.  Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. , 2002, The American journal of psychiatry.

[78]  Claus Svarer,et al.  Cortical and Subcortical 5-HT2A Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic Patients , 2008, Neuropsychopharmacology.

[79]  G. Milligan,et al.  Allosteric modulation of heterodimeric G-protein-coupled receptors. , 2007, Trends in pharmacological sciences.

[80]  S. Sealfon,et al.  Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex , 2003, The Journal of Neuroscience.

[81]  R. Andrade,et al.  Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex , 2007, Proceedings of the National Academy of Sciences.

[82]  J. Meador-Woodruff,et al.  NMDA receptors and schizophrenia. , 2007, Current opinion in pharmacology.

[83]  J. C. Winter,et al.  Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives , 1995, Psychopharmacology.

[84]  G. Aghajanian,et al.  Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. , 2000, The Journal of pharmacology and experimental therapeutics.